Tiotropium bromide

Drug Profile

Tiotropium bromide

Alternative Names: BA-679-BR; HGP 1011; Spiriva; Spiriva HandiHaler; Spiriva Respimat; Tiotropium; Tiotropium bromide monohydrate; Tiotropium HFA BAI; Tiotropium hydrofluoroalkane breath actuated inhaler; Tiotropium Respimat®

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Phase III Cystic fibrosis
  • Discontinued Lung cancer

Most Recent Events

  • 17 Feb 2017 Launched for Asthma (Adjunctive treatment, In children) in USA (Inhalation)
  • 16 Feb 2017 Registered for Asthma (Adjunctive treatment, In children) in USA (Inhalation)
  • 16 Feb 2017 Tiotropium bromide approved for Asthma (Adjunctive treatment, In children) under priority review status in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top